open access

Vol 8, No 5 (2004)
Artykuły redakcyjne
Published online: 2004-11-15
Get Citation

Treatment of primary aldosteronism - debate continues. Part II

Aleksander Prejbisz, Mariola Pęczkowska, Andrzej Januszewicz, Włodzimierz Januszewicz
Nadciśnienie tętnicze 2004;8(5):293-296.

open access

Vol 8, No 5 (2004)
Artykuły redakcyjne
Published online: 2004-11-15

Abstract

Primary aldosteronism has been first described by polish doctor Michał Lityński in 1953. Improved screening methods has showed that primary aldosteronism is more common than it has been previously suspected. It has been estimated that primary aldosteronsim affects 5–10% of patients with hypertension. Idiopathic bilateral adrenal hyperplasia and aldosterone producing adrenal adenoma are the leading causes of primary aldosteronsim. The diagnosis of primary aldosteronism must be confirmed by demonstrating autonomous aldosterone secretion with confirmatory testing. The subtype evaluation is based on biochemical and localizing methods. Because of the deleterious cardiovascular effects of excess aldosterone, normalization of circulating aldosterone or aldosterone receptor blockade should be part of the management plan for all patients with primary aldosteronism.

Abstract

Primary aldosteronism has been first described by polish doctor Michał Lityński in 1953. Improved screening methods has showed that primary aldosteronism is more common than it has been previously suspected. It has been estimated that primary aldosteronsim affects 5–10% of patients with hypertension. Idiopathic bilateral adrenal hyperplasia and aldosterone producing adrenal adenoma are the leading causes of primary aldosteronsim. The diagnosis of primary aldosteronism must be confirmed by demonstrating autonomous aldosterone secretion with confirmatory testing. The subtype evaluation is based on biochemical and localizing methods. Because of the deleterious cardiovascular effects of excess aldosterone, normalization of circulating aldosterone or aldosterone receptor blockade should be part of the management plan for all patients with primary aldosteronism.
Get Citation

Keywords

primary aldosteronism; prevalence; screening; diagnosis; treatment

About this article
Title

Treatment of primary aldosteronism - debate continues. Part II

Journal

Arterial Hypertension

Issue

Vol 8, No 5 (2004)

Pages

293-296

Published online

2004-11-15

Bibliographic record

Nadciśnienie tętnicze 2004;8(5):293-296.

Keywords

primary aldosteronism
prevalence
screening
diagnosis
treatment

Authors

Aleksander Prejbisz
Mariola Pęczkowska
Andrzej Januszewicz
Włodzimierz Januszewicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl